Diabetes Prevention Program Reauthorization Act of 2026
The source supplies the latest action, but no lifecycle stage.
Latest action (13 Aug 2026): Referred to the House Committee on Energy and Commerce.
What this bill does
H.R. 10086, the Diabetes Prevention Program Reauthorization Act of 2026, would renew federal funding authority for the National Diabetes Prevention Program, which is established under the Public Health Service Act. The bill replaces an outdated funding provision that authorized "such sums as may be necessary" for fiscal years 2010 through 2014 with specific dollar amounts for fiscal years 2027 through 2031: $39.3 million in 2027, rising incrementally each year to $59.3 million by 2031.
The bill primarily affects the operation of the National Diabetes Prevention Program itself, a federal initiative aimed at preventing or delaying the onset of type 2 diabetes. By setting clear funding levels for the coming years, the legislation would provide budgetary certainty for the agencies and organizations that administer or participate in the program, potentially including public health agencies and community-based diabetes prevention providers who rely on program funding.
The bill was introduced on August 13, 2026, by Rep. Mónica De La Cruz of Texas, along with a cosponsor, and has been referred to the House Committee on Energy and Commerce for consideration. As an introduced bill, it has not yet been voted on by the committee or the full House. It would need to pass committee review, a House floor vote, Senate approval, and receive the President's signature before becoming law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
13 Aug 2026
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 10086 do?
- H.R. 10086, the Diabetes Prevention Program Reauthorization Act of 2026, would renew federal funding authority for the National Diabetes Prevention Program, which is established under the Public Health Service Act. The bill replaces an outdated funding provision that authorized "such sums as may be necessary" for fiscal years 2010 through 2014 with specific dollar amounts for fiscal years 2027 through 2031: $39.3 million in 2027, rising incrementally each year to $59.3 million by 2031. The bill primarily affects the operation of the National Diabetes Prevention Program itself, a federal initiative aimed at preventing or delaying the onset of type 2 diabetes. By setting clear funding levels for the coming years, the legislation would provide budgetary certainty for the agencies and organizations that administer or participate in the program, potentially including public health agencies and community-based diabetes prevention providers who rely on program funding. The bill was introduced on August 13, 2026, by Rep. Mónica De La Cruz of Texas, along with a cosponsor, and has been referred to the House Committee on Energy and Commerce for consideration. As an introduced bill, it has not yet been voted on by the committee or the full House. It would need to pass committee review, a House floor vote, Senate approval, and receive the President's signature before becoming law.
- Has H.R. 10086 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 10086. Check the latest action and official source below.
- Who sponsored H.R. 10086?
- H.R. 10086 was sponsored by Rep. De La Cruz, Monica [R-TX-15] (R-TX), with 1 cosponsor.
- What's the latest action on H.R. 10086?
- Referred to the House Committee on Energy and Commerce. (13 Aug 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. De La Cruz, Monica [R-TX-15]
Combating Pasture Mealybug Act
Preventing the Financing of Illegal Synthetic Drugs Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.